Owkin announced that it has entered into a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin?s AI Scientist. Owkin and Sanofi have collaborated since 2021 through a EUR 90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi?s immunology pipeline.
This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built for Sanofi. These AI agents will work like intelligent assistants, autonomously performing complex tasks in drug research and development.
They will be deployed through K Pro, with the aim of complementing and reinforcing Sanofi?s existing agentic AI capabilities. K Pro combines multimodal patient data with specialized biological, agentic AI systems to support each stage of the pharmaceutical value chain, from early discovery through clinical development, while providing competitive intelligence, enabling faster, more informed, and more precise decisions. K Pro?s development is part of Owkin?s mission to achieve Biological Artificial Superintelligence to unlock new therapeutic discoveries beyond the limits of human cognition alone.
Owkin believes this technology will enable the pharmaceutical industry to address, and ultimately automate, some of the most complex challenges in R&D.
